This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 8, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of an underwritten public offering of 9,000,000 shares of its common stock, offered at a price to the public of
$19.00 per share. The gross proceeds to Isis from this offering are expected to be
$171.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Isis. The offering is expected to close on or about
May 14, 2013, subject to customary closing conditions. In addition, Isis has granted the underwriters a 30-day option to purchase at the public offering price up to an aggregate of 1,350,000 additional shares of its common stock. Isis anticipates using the net proceeds from the offering to increase its drug development activities, develop select drugs in its pipeline to later stages of development prior to partnering, and for general corporate and working capital purposes.
Goldman, Sachs & Co. and J. P. Morgan Securities LLC are acting as joint book-running managers in the offering. Stifel is acting as lead manager. BMO Capital Markets, Cowen and Company, LLC and Needham & Company are acting as co-managers.
The securities described above are being offered by Isis pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which became effective on
May 7, 2013. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at
http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to these securities may be obtained, when available, from Goldman, Sachs & Co. (Attn: Prospectus Department, 200 West Street,
New York, New York 10282, Fax: 212-902-9316 or Email at
firstname.lastname@example.org or by calling 1-866-471-2526) or J.P. Morgan Securities LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by calling 866-803-9204). Electronic copies of the prospectus supplements may be obtained by visiting EDGAR on the SEC's website at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.